Eddy Karnieli

Summary

Affiliation: Technion-Israel Institute of Technology
Country: Israel

Publications

  1. doi request reprint The growing prevalence of obesity worldwide is an increasing concern. Preface
    Eddy Karnieli
    Institute of Endocrinology, Diabetes, and Metabolism, Rambam Medical Center, R B Rapaport Faculty of Medicine Technion, 12 Halia Street, Haifa 31096, Israel
    Endocrinol Metab Clin North Am 37:xvii-xviii. 2008
  2. doi request reprint Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: from physiology to pathology
    Eddy Karnieli
    Institute of Endocrinology, Diabetes and Metabolism, 12 Haliah St, PO Box 9602, Rambam Medical Center, Haifa 31096, Israel
    Am J Physiol Endocrinol Metab 295:E38-45. 2008
  3. ncbi request reprint Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements
    Michal Armoni
    Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center and B Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa 31096, Israel
    J Biol Chem 280:34786-95. 2005
  4. ncbi request reprint FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity
    Michal Armoni
    Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center, Haifa, Israel
    J Biol Chem 281:19881-91. 2006
  5. ncbi request reprint Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect
    Michal Armoni
    Institute of Endocrinology, Diabetes, and Metabolism, Rambam Medical Center and Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa 31096, Israel
    J Biol Chem 278:30614-23. 2003
  6. ncbi request reprint Transcriptional regulation of the GLUT4 gene: from PPAR-gamma and FOXO1 to FFA and inflammation
    Michal Armoni
    Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center, Technion Israel Institute of Technology, Haifa, 31096, Israel
    Trends Endocrinol Metab 18:100-7. 2007
  7. doi request reprint GLUT4 in murine bone growth: from uptake and translocation to proliferation and differentiation
    Gila Maor
    Department of Anatomy and Cell Biology, Rappaport Faculty of Medicine, Tel Aviv University, Israel
    Am J Physiol Endocrinol Metab 300:E613-23. 2011
  8. ncbi request reprint The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression
    Fabiana Schwartzenberg-Bar-Yoseph
    Institute of Endocrinology, Diabetes, and Metabolism, Rambam Medical Center and B Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Cancer Res 64:2627-33. 2004
  9. ncbi request reprint PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro
    Michal Armoni
    Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center, Technion Israel Institute of Technology, Haifa 31096, Israel
    J Clin Endocrinol Metab 87:5312-24. 2002
  10. pmc Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE)
    Eddy Karnieli
    Endocrinology, Diabetes and Metabolism, Rambam Medical Center and Rappaport Faculty of Medicine, Technion, 12 Halia St, Samy Ofer Tower, Fl 8, Haifa, 31096, Israel
    Drugs Aging 30:167-75. 2013

Detail Information

Publications16

  1. doi request reprint The growing prevalence of obesity worldwide is an increasing concern. Preface
    Eddy Karnieli
    Institute of Endocrinology, Diabetes, and Metabolism, Rambam Medical Center, R B Rapaport Faculty of Medicine Technion, 12 Halia Street, Haifa 31096, Israel
    Endocrinol Metab Clin North Am 37:xvii-xviii. 2008
  2. doi request reprint Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: from physiology to pathology
    Eddy Karnieli
    Institute of Endocrinology, Diabetes and Metabolism, 12 Haliah St, PO Box 9602, Rambam Medical Center, Haifa 31096, Israel
    Am J Physiol Endocrinol Metab 295:E38-45. 2008
    ..The present review focuses on the interplay among hormonal, nutritional, and transcription factors in the regulation of GLUT4 transcription in health and sickness...
  3. ncbi request reprint Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements
    Michal Armoni
    Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center and B Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa 31096, Israel
    J Biol Chem 280:34786-95. 2005
    ....
  4. ncbi request reprint FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity
    Michal Armoni
    Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center, Haifa, Israel
    J Biol Chem 281:19881-91. 2006
    ..The newly identified FOXO1-binding site on the PPARgamma2 promoter may serve as a therapeutic target for type 2 diabetes...
  5. ncbi request reprint Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect
    Michal Armoni
    Institute of Endocrinology, Diabetes, and Metabolism, Rambam Medical Center and Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa 31096, Israel
    J Biol Chem 278:30614-23. 2003
    ..These data suggest a novel mechanism by which Rg exerts its antidiabetic effects via detaching PPARgamma from the GLUT4 gene promoter, thus leading to increased GLUT4 expression and enhanced insulin sensitivity...
  6. ncbi request reprint Transcriptional regulation of the GLUT4 gene: from PPAR-gamma and FOXO1 to FFA and inflammation
    Michal Armoni
    Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center, Technion Israel Institute of Technology, Haifa, 31096, Israel
    Trends Endocrinol Metab 18:100-7. 2007
    ....
  7. doi request reprint GLUT4 in murine bone growth: from uptake and translocation to proliferation and differentiation
    Gila Maor
    Department of Anatomy and Cell Biology, Rappaport Faculty of Medicine, Tel Aviv University, Israel
    Am J Physiol Endocrinol Metab 300:E613-23. 2011
    ..In growing bone, the IGF-IR pathway stimulates Glut4 translocation and enhances glucose uptake. Moreover, intact Glut4 cellular levels and translocation machinery are essential for early skeletal growth...
  8. ncbi request reprint The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression
    Fabiana Schwartzenberg-Bar-Yoseph
    Institute of Endocrinology, Diabetes, and Metabolism, Rambam Medical Center and B Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Cancer Res 64:2627-33. 2004
    ..This, in turn, would be predicted to facilitate tumor growth...
  9. ncbi request reprint PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro
    Michal Armoni
    Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center, Technion Israel Institute of Technology, Haifa 31096, Israel
    J Clin Endocrinol Metab 87:5312-24. 2002
    ..Taken together, the data suggest that the GLUT4 gene is a downstream target of PAX3/FKHR and that GLUT4 is aberrantly transactivated by this oncoprotein both in vivo and in vitro...
  10. pmc Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE)
    Eddy Karnieli
    Endocrinology, Diabetes and Metabolism, Rambam Medical Center and Rappaport Faculty of Medicine, Technion, 12 Halia St, Samy Ofer Tower, Fl 8, Haifa, 31096, Israel
    Drugs Aging 30:167-75. 2013
    ..The aim of this study was to evaluate the response to initiation of once-daily insulin detemir in patients aged ≥75 years with type 2 diabetes mellitus (T2DM) treated with one or more oral antidiabetic drugs (OADs)...
  11. ncbi request reprint Inhibin B in men with severe obesity and after weight reduction following gastroplasty
    Hadas Globerman
    Institute of Endocrinology, Diabetes and Metabolism, Rambam Medical Center, Haifa, Israel
    Endocr Res 31:17-26. 2005
    ..In conclusion, Serum inhibin B levels in obese men may be low. This may be due to relative hypogonadotropic (also low FSH) hypogonadism...
  12. ncbi request reprint A single treatment with IL-4 via retrovirally transduced lymphocytes partially protects against diabetes in BioBreeding (BB) rats
    Danny Zipris
    The Institute of Endocrinology, Diabetes, and Metabolism, Rambam Medical Center B Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    JOP 3:76-82. 2002
    ..The BioBreeding rat is used as an animal model for the study of human Type 1 diabetes. In spite of a severe lymphopenia, these animals develop spontaneous diabetes at the age of 10-12 weeks...
  13. doi request reprint Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial
    M Davies
    Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
    Diabetes Obes Metab 10:387-99. 2008
    ..This subgroup analysis investigated the initiation of once-daily glargine therapy in patients suboptimally controlled on multiple OADs...
  14. doi request reprint The metabolic syndrome--from insulin resistance to obesity and diabetes
    Emily Jane Gallagher
    Mount Sinai Medical Center, Department of Medicine, Division of Endocrinology, Diabetes, and Bone Diseases, One Gustave L Levy Place, Box 1055, New York, NY 10029 6574, USA
    Endocrinol Metab Clin North Am 37:559-79, vii. 2008
    ..Greater insight into the mechanism(s) behind the syndrome may improve our understanding of how to prevent and best manage this complex condition...
  15. doi request reprint Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
    Nish Chaturvedi
    International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College Healthcare NHS Trust, London, UK
    Lancet 372:1394-402. 2008
    ..We therefore designed the DIabetic REtinopathy Candesartan Trials (DIRECT) Programme to assess whether candesartan could reduce the incidence and progression of retinopathy in type 1 diabetes...
  16. doi request reprint Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
    Anne Katrin Sjølie
    Department of Ophthalmology, Odense University Hospital, Odense, Denmark
    Lancet 372:1385-93. 2008
    ..Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people with type 2 diabetes...